Biosimilar Antibodies

Lorvotuzumab Biosimilar – Anti-NCAM1, CD56 mAb – Research Grade, ProteoGenix, PX-TA1047

Description of Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb - Research Grade Introduction Lorvotuzumab Biosimilar, also known as Anti-NCAM1, CD56 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Lorvotuzumab. It is a promising therapeutic agent that has shown potential in the treatment of various cancers, particularly those that express the neural cell adhesion molecule 1 (NCAM1) or CD56. In this article, we will provide a comprehensive scientific description of Lorvotuzumab Biosimilar, including its structure, activity, and potential applications. Structure of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is a humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the target antigen, NCAM1 or CD56. Activity of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is a potent antibody that specifically targets the NCAM1 or CD56 protein. This protein is highly expressed in a variety of cancers, including small cell lung cancer, ovarian cancer, and multiple myeloma. By binding to NCAM1 or CD56, Lorvotuzumab Biosimilar inhibits the growth and survival of cancer cells and also activates the immune system to attack and destroy these cells. In addition to its direct anti- cancer activity, Lorvotuzumab Biosimilar has also been shown to enhance the effects of other anti- cancer therapies, such as chemotherapy and radiotherapy. This is due to its ability to sensitize cancer cells to these treatments, making them more susceptible to their effects. Potential Applications of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various cancers. Some of these trials are focused on its use as a single agent, while others are investigating its potential in combination with other therapies. One of the most promising applications of Lorvotuzumab Biosimilar is in the treatment of small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer that is often resistant to traditional therapies. However, early clinical trials have shown that Lorvotuzumab Biosimilar, either alone or in combination with chemotherapy, can significantly improve response rates and overall survival in patients with SCLC. Other potential applications of Lorvotuzumab Biosimilar include the treatment of ovarian cancer, multiple myeloma, and neuroblastoma. These cancers also express high levels of NCAM1 or CD56, making them potential targets for this antibody. Conclusion In summary, Lorvotuzumab Biosimilar is a promising therapeutic agent that specifically targets the NCAM1 or CD56 protein, which is highly expressed in various cancers. Its structure, activity, and potential applications make it a promising candidate for the treatment of cancers that are currently difficult to treat. With ongoing clinical trials, we hope to see Lorvotuzumab Biosimilar become a valuable addition to the arsenal of anti- cancer therapies.

Losatuxizumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1457-

Lumivatamig Biosimilar – Research Grade, ProteoGenix, PX-TA2495-100

Lumretuzumab Biosimilar – Anti-ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1357

Description of Lumretuzumab Biosimilar - Anti-ERBB3 mAb - Research Grade General information on Anti-ERBB3[Homo sapiens] (Lumretuzumab) Monoclonal Antibody Lumretuzumab has been investigated for the treatment of Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer.

Lupartumab Biosimilar – Anti-LYPD3 mAb – Research Grade, ProteoGenix, PX-TA1434

Description of Lupartumab Biosimilar - Anti-LYPD3 mAb - Research Grade General information on Anti-LYPD3[Homo sapiens] (Lupartumab) Monoclonal Antibody Lupartumab has been investigated for the treatment of Solid tumours.

Luspatercept Biosimilar – Anti-GDF11 fusion protein – Research Grade, ProteoGenix, PX-TA2101

Description of Luspatercept Biosimilar - Anti-GDF11 fusion protein - Research Grade Luspatercept Biosimilar: A Novel Anti-GDF11 Fusion Protein Introduction Luspatercept Biosimilar is a promising new therapeutic agent that has been developed as a biosimilar to the FDA-approved drug, Luspatercept. This novel drug is an anti-GDF11 fusion protein that has shown great potential in treating a variety of diseases. In this article, we will explore the structure, activity, and potential applications of Luspatercept Biosimilar in the field of medicine. Structure of Luspatercept Biosimilar Luspatercept Biosimilar is a fusion protein that consists of two components: a human IgG1 Fc fragment and a modified form of the protein GDF11. The human IgG1 Fc fragment serves as a scaffold for the GDF11 protein, allowing for increased stability and half-life. The modified GDF11 protein is designed to specifically target and bind to its therapeutic target, making it highly specific and effective. Antibody Activity of Luspatercept Biosimilar As an anti-GDF11 fusion protein, Luspatercept Biosimilar acts as an antibody that targets and neutralizes the activity of GDF11. GDF11 is a member of the transforming growth factor-beta (TGF-β) superfamily and plays a crucial role in regulating cell growth and differentiation. However, excessive levels of GDF11 have been linked to various diseases, including anemia and cancer. Luspatercept Biosimilar binds to GDF11, preventing it from interacting with its receptors and inhibiting its activity. Applications of Luspatercept Biosimilar Luspatercept Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases. Here are some potential applications of this novel drug: 1. Treatment of Anemia Anemia is a condition characterized by a decrease in the number of red blood cells or hemoglobin in the blood, resulting in reduced oxygen delivery to tissues. Luspatercept Biosimilar has shown great potential in treating anemia associated with myelodysplastic syndromes (MDS) and beta-thalassemia. In clinical trials, it has been shown to increase the production of red blood cells and improve the symptoms of anemia. 2. Cancer Therapy GDF11 has been implicated in the development and progression of various cancers, including prostate cancer and breast cancer. By targeting and neutralizing GDF11, Luspatercept Biosimilar has the potential to inhibit the growth and spread of cancer cells. Clinical trials are currently underway to evaluate the efficacy of this drug in cancer therapy. 3. Regenerative Medicine GDF11 has also been found to play a role in tissue regeneration and repair. As Luspatercept Biosimilar targets and neutralizes GDF11, it has the potential to promote tissue regeneration and repair in conditions such as heart failure and muscle wasting diseases. 4. Other Potential Applications Apart from the above-mentioned applications, Luspatercept Biosimilar is also being investigated for its potential in treating other diseases, including pulmonary arterial hypertension, diabetic nephropathy, and osteoporosis. Conclusion In conclusion, Luspatercept Biosimilar is a promising new therapeutic agent that acts as an anti-GDF11 fusion protein. Its unique structure and antibody activity make it a highly specific and effective drug for the treatment of various diseases. With ongoing clinical trials, this drug has the potential to make a significant impact in the field of medicine and improve the lives of patients suffering from various diseases.

Lutikizumab Biosimilar – Anti-IL1A , IL1B mAb – Research Grade, ProteoGenix, PX-TA1440

Description of Lutikizumab Biosimilar - Anti-IL1A , IL1B mAb - Research Grade General information on Anti-IL1A /IL1B[Homo sapiens] (Lutikizumab) Monoclonal Antibody Lutikizumab is investigated for the treatment of Knee Osteoarthritis.

M802 Biosimilar – Anti-Bispecific mAb – Research Grade, ProteoGenix, PX-TA1899

Description of M802 Biosimilar - Anti-Bispecific mAb - Research Grade M802 Biosimilar – Anti-Bispecific mAb – Research Grade: A Revolutionary Treatment for Multiple Diseases The M802 Biosimilar is a groundbreaking antibody therapy that targets multiple diseases. This research grade medication is a biosimilar of the widely used anti-bispecific monoclonal antibody (mAb). It has been developed using advanced biotechnology and has shown promising results in preclinical trials. In this article, we will explore the structure, activity, and potential applications of M802 Biosimilar in the field of medicine. Structure of M802 Biosimilar M802 Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced in a laboratory to mimic the antibodies naturally produced by the immune system. It is a biosimilar of the anti-bispecific mAb, which is a type of antibody that targets two different antigens simultaneously. The structure of M802 Biosimilar is similar to the anti-bispecific mAb, with some minor differences that allow it to target multiple diseases. The M802 Biosimilar is composed of two heavy chains and two light chains, which are connected by disulfide bonds. These chains are made up of amino acids, which are arranged in a specific sequence to form the unique structure of the antibody. The variable region of the antibody, which is responsible for binding to the target antigens, is highly specific and can recognize a wide range of disease-causing molecules. Activity of M802 Biosimilar The primary function of M802 Biosimilar is to bind to specific antigens and neutralize their activity. This is achieved through the binding of the variable region of the antibody to the target antigens, which prevents them from interacting with their respective receptors and causing disease. In addition to this, M802 Biosimilar also activates the immune system to eliminate the bound antigens, further enhancing its therapeutic effect. One of the key features of M802 Biosimilar is its ability to target multiple diseases at once. This is made possible by the unique structure of the antibody, which allows it to bind to multiple antigens simultaneously. This makes it a highly effective treatment for diseases that involve multiple targets, such as cancer and autoimmune disorders. Applications of M802 Biosimilar M802 Biosimilar has a wide range of potential applications in the field of medicine. Its ability to target multiple diseases makes it a versatile treatment option for a variety of conditions. Some of the potential applications of M802 Biosimilar include: Cancer: M802 Biosimilar has shown promising results in preclinical trials for the treatment of various types of cancer. Its ability to target multiple antigens makes it a highly effective treatment for tumors that have multiple mutations. Autoimmune disorders: M802 Biosimilar has the potential to treat autoimmune disorders, such as rheumatoid arthritis, by targeting the specific antigens that are responsible for the disease. Infectious diseases: The ability of M802 Biosimilar to activate the immune system makes it a potential treatment for infectious diseases, such as viral infections, by enhancing the body’s natural defense mechanisms. Other diseases: M802 Biosimilar may also have applications in the treatment of other diseases, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. In conclusion, the M802 Biosimilar is a revolutionary treatment option that has the potential to target multiple diseases simultaneously. Its unique structure and activity make it a highly effective therapy with a wide range of potential applications. With further research and clinical trials, M802 Biosimilar has the potential to revolutionize the treatment of various diseases and improve the lives of patients worldwide.

Magrolimab Biosimilar – Anti-CD47 mAb – Research Grade, ProteoGenix, PX-TA1561

Description of Magrolimab Biosimilar - Anti-CD47 mAb - Research Grade Introduction Magrolimab Biosimilar, also known as Anti-CD47 monoclonal antibody (mAb), is a promising therapeutic agent that has shown potential in treating various types of cancers. This novel biosimilar is being developed by several pharmaceutical companies as a more affordable alternative to the original anti-CD47 mAb. In this article, we will explore the structure, activity, and potential applications of Magrolimab Biosimilar in cancer treatment. Structure of Magrolimab Biosimilar Magrolimab Biosimilar is a monoclonal antibody that specifically targets the CD47 protein. It is a humanized IgG4 antibody, meaning it is derived from human antibodies and has been modified to reduce its immunogenicity. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, connected by disulfide bonds. The variable region of Magrolimab Biosimilar is responsible for binding to CD47, while the constant region is responsible for activating the immune system. The binding site of the antibody is located on the Fc region, which is important for its therapeutic activity. Activity of Magrolimab Biosimilar The main mechanism of action of Magrolimab Biosimilar is through its binding to CD47. CD47 is a protein that is overexpressed on the surface of cancer cells, allowing them to evade detection and destruction by the immune system. By binding to CD47, Magrolimab Biosimilar blocks its interaction with the SIRPα receptor on macrophages, thus preventing the “don’t eat me” signal and allowing the immune system to recognize and eliminate cancer cells. In addition to its direct anti- cancer activity, Magrolimab Biosimilar also has immunomodulatory effects. It can activate macrophages, dendritic cells, and natural killer cells, leading to enhanced phagocytosis and production of pro-inflammatory cytokines. This further boosts the immune response against cancer cells. Potential Applications of Magrolimab Biosimilar Magrolimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancers, including acute myeloid leukemia, non-Hodgkin’s lymphoma, and solid tumors such as ovarian, breast, and lung cancer. One of the advantages of Magrolimab Biosimilar is its potential to be used in combination with other cancer therapies. It has been shown to synergize with chemotherapy, radiation therapy, and other immunotherapies, leading to improved efficacy and reduced toxicity. Moreover, Magrolimab Biosimilar has the potential to be used in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By blocking the CD47-SIRPα interaction, it can prevent the destruction of healthy cells by the immune system. Conclusion Magrolimab Biosimilar is a promising anti-CD47 monoclonal antibody that has the potential to revolutionize cancer treatment. Its unique structure and mechanism of action make it a highly effective and versatile therapeutic agent. With ongoing research and clinical trials, Magrolimab Biosimilar has the potential to improve the lives of cancer patients and pave the way for more affordable and accessible treatments. Keywords: Magrolimab Biosimilar, Anti-CD47 monoclonal antibody, cancer treatment, structure, activity, applications

Matuzumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1041-